040 - 6945 8201
www.pihealthcancerhospital.com
Hyderabad | Nizamabad

Pi Health CANCER HOSPITAL
Revolutionary Care. Transformative Research.

Protocol Title: A Pilot, Open-label Study of Tislelizumab in Combination With Chemotherapy in First-line treatment of Unresectable/Metastatic Non-small Cell Lung Cancer or Recurrent / Metastatic Squamous Cell Head and Neck Cancer

Study Treatment: Tislelizumab (Study Drug) + Chemotherapy (Platinum Agent, Pemetrexed, Taxane)

Key Inclusion criteria

Patients affected by histologically or cytologically documented solid tumor malignancies as described below:

Cohort 1: Unresectable Locally Advanced/Metastatic Non- Small Cell Lung Cancer

- **Locally advanced or recurrent NSCLC ALK / EGFR Mutations Negative that is not eligible for curative surgery and/or definitive radiotherapy with or without chemoradiotherapy, or metastatic non squamous or squamous NSCLC.**
- **No prior systemic treatment for metastatic NSCLC. Patients who have received prior neoadjuvant, adjuvant chemotherapy, radiotherapy, or chemoradiotherapy with curative intent for nonmetastatic disease must have experienced a disease-free interval of ≥ 6 months from the last dose of chemotherapy and/or radiotherapy prior to signing informed consent.**

Cohort 2: Recurrent/Metastatic Squamous Cell Head and Neck Cancer

- **Recurrent or metastatic HNSCC that is not amenable to by local curative therapies with surgery or radiation.**
- **Primary tumor site of oral cavity, oropharynx, hypopharynx, or larynx.**

Patients with a primary tumor site of nasopharynx are excluded. (Note: human papillomavirus (HPV) status will not be required prior to entering the study)

- **No prior systemic therapy administered in recurrent or metastatic setting. Systemic therapy which is given as part of multimodal treatment for locally advanced disease is allowed.**
- **Tumor progression or recurrence ≥ 6 months after last dose of platinum therapy for patients who received multimodality treatment for locally advanced or locally recurrent disease**

For further more information please contact

Dr. A . Venugopal
HOD Clinical Director - Medical Oncology
Senior Consultant Medical Oncologist & Hemato - Oncologist
MD (General Medicine) DM (Medical Oncology)
MRCP - SCE Medical Oncology (UK) ECMO
Mob.No: 9980707675
venugopal.arroju@picancerhospital.ai

Research Team
Lakshmaiah.T
Mob.No: 9966596459

Research Team
Nikhitha Gujja
Mob.No: 8367344978